Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Edgewise Therapeutics, Inc.

EWTX · Nasdaq · CIK 0001710072 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

38 Form 4 transaction lines observed in the same window
23 sales · 15 option, withholding, award, gift or other lines

Last qualifying purchase2025-11-11 · Fox Jonathan C · $199.4K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesHigh
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Donovan Joanne M.CMO
▼○▼○▼▼
Russell Alan JChief Scientific Officer
○▼○▼
MOORE JOHN RGeneral Counsel
○▼
KOCH KEVINPresident and CEO
○▼
Derakhshan BehradChief Business Officer
○▼
Fox Jonathan CDirector
○○
● Purchase▼ Sale○ Other

—

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-11-11 · Fox Jonathan C.

Recent Form 4 activity

1Purchases
33Sales
25Other Form 4 lines
17SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING23 sale line(s) · context only
OTHER15 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
11,224,347
Previous report
9,543,843
Avg daily volume
2,003,524
Days to cover
5.6

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2025-11-11Fox Jonathan CPurchase (P)Common Stock10,700USD 18.64USD 199,448SEC filing ↗
2025-04-03Thompson Peter A.Purchase (P)Common Stock496,771USD 20.13USD 10,000,000SEC filing ↗
2025-04-03ORBIMED ADVISORS LLC; OrbiMed Capital GP VI LLC; OrbiMed Genesis GP LLCPurchase (P)Common Stock496,771USD 20.13USD 10,000,000SEC filing ↗
2024-01-23Thompson Peter A.Purchase (P)Common Stock454,545USD 11.00USD 4,999,995SEC filing ↗
2024-01-23ORBIMED ADVISORS LLC; OrbiMed Capital GP VI LLC; OrbiMed Genesis GP LLCPurchase (P)Common Stock454,545USD 11.00USD 4,999,995SEC filing ↗
2023-12-26Fox Jonathan CPurchase (P)Common Stock10,857USD 9.30USD 100,970SEC filing ↗
2022-09-16Thompson Peter A.Purchase (P)Common Stock484,496USD 10.32USD 4,999,999SEC filing ↗
2022-09-16ORBIMED ADVISORS LLC; OrbiMed Capital GP VI LLC; OrbiMed Genesis GP LLCPurchase (P)Common Stock484,496USD 10.32USD 4,999,999SEC filing ↗
2022-09-14Novo Holdings A/SPurchase (P)COMMON STOCK484,496USD 10.32USD 4,999,999SEC filing ↗
2022-05-18Thompson Peter A.Purchase (P)Common Stock138,000USD 7.21USD 994,980SEC filing ↗
2022-05-18ORBIMED ADVISORS LLC; OrbiMed Capital GP VI LLC; OrbiMed Genesis GP LLCPurchase (P)Common Stock138,000USD 7.21USD 994,980SEC filing ↗
2021-03-30Thompson Peter A.Purchase (P)Common Stock359,375USD 16.00USD 5,750,000SEC filing ↗
2021-03-30ROOT JONATHAN DPurchase (P)Common Stock15,625USD 16.00USD 250,000SEC filing ↗
2021-03-30ORBIMED ADVISORS LLC; OrbiMed Capital GP VI LLC; OrbiMed Genesis GP LLCPurchase (P)Common Stock359,375USD 16.00USD 5,750,000SEC filing ↗
2021-03-30Novo Holdings A/SPurchase (P)COMMON STOCK625,000USD 16.00USD 10,000,000SEC filing ↗

Form 4 evidence

59 transaction lines in the latest 365-day window; 281 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-01Fox Jonathan CAward / grant (A)Common Stock308USD 0.00USD 0SEC filing ↗
2026-08-13Donovan Joanne M.Sale (S)Common Stock2,919USD 43.41USD 126,714SEC filing ↗
2026-08-12Russell Alan JSale (S)Common Stock5,901USD 43.73USD 258,060SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-01Fox Jonathan CAward / grant (A)Common Stock308USD 0.00USD 0SEC filing ↗
2026-08-13Donovan Joanne M.Sale (S)Common Stock2,919USD 43.41USD 126,714SEC filing ↗
2026-08-12Russell Alan JSale (S)Common Stock5,901USD 43.73USD 258,060SEC filing ↗
2026-08-12Russell Alan JOption exercise / conversion (M)Common Stock12,812USD 0.00USD 0SEC filing ↗
2026-08-12MOORE JOHN RSale (S)Common Stock5,016USD 43.83USD 219,830SEC filing ↗
2026-08-12MOORE JOHN ROption exercise / conversion (M)Common Stock12,499USD 0.00USD 0SEC filing ↗
2026-08-12KOCH KEVINSale (S)Common Stock17,971USD 43.68USD 785,050SEC filing ↗
2026-08-12KOCH KEVINOption exercise / conversion (M)Common Stock39,844USD 0.00USD 0SEC filing ↗
2026-08-12Donovan Joanne M.Sale (S)Common Stock6,522USD 43.85USD 285,998SEC filing ↗
2026-08-12Donovan Joanne M.Option exercise / conversion (M)Common Stock12,812USD 0.00USD 0SEC filing ↗
2026-08-12Derakhshan BehradSale (S)Common Stock5,100USD 43.81USD 223,420SEC filing ↗
2026-08-12Derakhshan BehradOption exercise / conversion (M)Common Stock13,281USD 0.00USD 0SEC filing ↗
2026-07-01Russell Alan JSale (S)Common Stock200,000USD 39.41USD 7,882,000SEC filing ↗
2026-07-01Russell Alan JOption exercise / conversion (M)Common Stock200,000USD 0.36USD 71,195SEC filing ↗
2026-07-01Fox Jonathan CAward / grant (A)Common Stock319USD 0.00USD 0SEC filing ↗
2026-05-05Donovan Joanne M.Sale (S)Common Stock50,000USD 38.57USD 1,928,500SEC filing ↗
2026-05-05Donovan Joanne M.Option exercise / conversion (M)Common Stock50,000USD 7.08USD 354,000SEC filing ↗
2026-05-04Donovan Joanne M.Sale (S)Common Stock5,230USD 31.29USD 163,647SEC filing ↗
2026-04-01Fox Jonathan CAward / grant (A)Common Stock339USD 0.00USD 0SEC filing ↗
2026-04-01Donovan Joanne M.Sale (S)Common Stock28,662USD 32.31USD 926,069SEC filing ↗
2026-04-01Donovan Joanne M.Option exercise / conversion (M)Common Stock28,662USD 7.08USD 202,927SEC filing ↗
2026-03-31Donovan Joanne M.Sale (S)Common Stock21,338USD 32.12USD 685,377SEC filing ↗
2026-03-31Donovan Joanne M.Option exercise / conversion (M)Common Stock21,338USD 7.08USD 151,073SEC filing ↗
2026-03-27Donovan Joanne M.Sale (S)Common Stock16,358USD 30.98USD 506,771SEC filing ↗
2026-01-21Edris BadreddinSale (S)Common Stock115,471USD 29.44USD 3,399,466SEC filing ↗
2026-01-21Edris BadreddinOption exercise / conversion (M)Common Stock115,471USD 1.47USD 170,264SEC filing ↗
2026-01-02Fox Jonathan CAward / grant (A)Common Stock473USD 0.00USD 0SEC filing ↗
2025-11-12Russell Alan JSale (S)Common Stock100,000USD 21.12USD 2,112,000SEC filing ↗
2025-11-12Russell Alan JOption exercise / conversion (M)Common Stock100,000USD 0.18USD 18,000SEC filing ↗
2025-11-11Fox Jonathan CPurchase (P)Common Stock10,700USD 18.64USD 199,448SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerEWTX
CIK0001710072
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history281 transaction lines from 2021-03-30 to 2026-10-01
20 P purchase lines · 145 S sale lines · 116 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.